CL2013003248A1 - Composición inmunogenica que comprende una glucoproteina g de los virus hendra y nipah y un complejo inmunoestimulante; método para producir una respuesta de anticuerpo neutralizante contra un virus hendra y/o nipah en un sujeto. - Google Patents
Composición inmunogenica que comprende una glucoproteina g de los virus hendra y nipah y un complejo inmunoestimulante; método para producir una respuesta de anticuerpo neutralizante contra un virus hendra y/o nipah en un sujeto.Info
- Publication number
- CL2013003248A1 CL2013003248A1 CL2013003248A CL2013003248A CL2013003248A1 CL 2013003248 A1 CL2013003248 A1 CL 2013003248A1 CL 2013003248 A CL2013003248 A CL 2013003248A CL 2013003248 A CL2013003248 A CL 2013003248A CL 2013003248 A1 CL2013003248 A1 CL 2013003248A1
- Authority
- CL
- Chile
- Prior art keywords
- hendra
- subject
- immunogenic composition
- glycoprotein
- nipah
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56983—Viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A61K2039/541—Mucosal route
- A61K2039/544—Mucosal route to the airways
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
- A61K2039/552—Veterinary vaccine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
- C12N2710/24141—Use of virus, viral particle or viral elements as a vector
- C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18211—Henipavirus, e.g. hendra virus
- C12N2760/18222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18211—Henipavirus, e.g. hendra virus
- C12N2760/18234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
- G01N2333/08—RNA viruses
- G01N2333/115—Paramyxoviridae, e.g. parainfluenza virus
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2469/00—Immunoassays for the detection of microorganisms
- G01N2469/20—Detection of antibodies in sample from host which are directed against antigens from microorganisms
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Biotechnology (AREA)
- Pulmonology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Analytical Chemistry (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Cell Biology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Biophysics (AREA)
Abstract
La invención se relaciona con una composición inmunogénica porque comprende una glucoproteína G de los virus Hendra donde dicho fragmento consiste en los aminoácidos 73 a 604 de (SEQ ID N° 2) o una secuencia al menos 90% idéntica de la misma, un complejo inmunoestimulante (ISC) donde dicho complejo ISC comprende una saponina, un fosfolípido y un esteroide; y uno o más excipientes, donde la concentración del fragmento soluble de la glucoproteína G del virus Hendra en la composición es de 5-100 ?g/ml de ISC y donde dicha composición suscita la producción de anticuerpos neutralizantes contra el virus Hendra después de su administración a un sujeto. Así mismo reivindica un método para diferenciar un sujeto vacunado con la composición inmunogénica del invento, de un sujeto expuesto a un virus Hendra y/o Nipah porque comprende detectar la presencia de un anticuerpo en una muestra biológica aislada del sujeto contra por lo menos una de cualquiera de las siguientes proteínas virales HeV y/o NiV seleccionadas del grupo que consiste en una proteína de fusión (F), una proteína de la matriz (M), una fosfoproteína (P), una proteína grande (L) y una proteína de la nucleocápside (N). Además, describe el uso de la composición inmunogénica del invento porque sirve para la fabricación de un medicamento útil en el tratamiento de un sujeto con una infección de virus Hendra.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161485992P | 2011-05-13 | 2011-05-13 |
Publications (1)
Publication Number | Publication Date |
---|---|
CL2013003248A1 true CL2013003248A1 (es) | 2014-08-08 |
Family
ID=47177303
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CL2013003248A CL2013003248A1 (es) | 2011-05-13 | 2013-11-13 | Composición inmunogenica que comprende una glucoproteina g de los virus hendra y nipah y un complejo inmunoestimulante; método para producir una respuesta de anticuerpo neutralizante contra un virus hendra y/o nipah en un sujeto. |
Country Status (18)
Country | Link |
---|---|
US (1) | US20150050305A1 (es) |
EP (2) | EP2707025B8 (es) |
JP (4) | JP2014516955A (es) |
KR (2) | KR20140053906A (es) |
CN (2) | CN104244974A (es) |
AU (2) | AU2012256000B2 (es) |
BR (1) | BR112013029309A8 (es) |
CA (1) | CA2836098C (es) |
CL (1) | CL2013003248A1 (es) |
CO (1) | CO6940373A2 (es) |
ES (2) | ES2963147T3 (es) |
HK (1) | HK1247833A1 (es) |
MX (1) | MX352604B (es) |
PT (1) | PT2707025T (es) |
RU (1) | RU2681529C2 (es) |
UA (1) | UA114086C2 (es) |
WO (1) | WO2012158643A1 (es) |
ZA (1) | ZA201308701B (es) |
Families Citing this family (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MX2012003126A (es) | 2009-09-21 | 2012-06-19 | Gilead Sciences Inc | Procesos e intermedios para la preparacion de analogos de 1'-carbonucleosidos sustituidos. |
MX2013000744A (es) | 2010-07-22 | 2013-03-07 | Gilead Sciences Inc | Metodos y compuestos para tratar infecciones virales por paramyxoviridae. |
CA2837582C (en) * | 2011-05-27 | 2021-03-02 | Merial Limited | Genetic vaccines against hendra virus and nipah virus |
CN109078179A (zh) * | 2013-09-05 | 2018-12-25 | 硕腾服务有限责任公司 | Hendra和Nipah病毒G糖蛋白免疫原性组合物 |
KR20190009840A (ko) * | 2013-09-19 | 2019-01-29 | 조에티스 서비시즈 엘엘씨 | 유성 아쥬반트 |
US20160331829A1 (en) * | 2013-12-16 | 2016-11-17 | Zoetis Services Llc | Hendra and nipah virus g glycoprotein immunogenic compositions |
TWI767201B (zh) | 2014-10-29 | 2022-06-11 | 美商基利科學股份有限公司 | 絲狀病毒科病毒感染之治療 |
MA42819A (fr) | 2015-09-16 | 2018-07-25 | Gilead Sciences Inc | Procédés pour le traitement d'infections virales à arenaviridae et coronaviridae |
AR109621A1 (es) * | 2016-10-24 | 2018-12-26 | Janssen Pharmaceuticals Inc | Formulaciones de vacunas contra glucoconjugados de expec |
TW201836615A (zh) | 2017-03-14 | 2018-10-16 | 美商基利科學股份有限公司 | 治療貓冠狀病毒感染之方法 |
CN108624602B (zh) * | 2017-03-24 | 2020-10-16 | 华中农业大学 | 一株具有阻断活性的抗尼帕病毒g蛋白的单克隆抗体及其应用 |
AU2018262501B2 (en) | 2017-05-01 | 2020-12-10 | Gilead Sciences, Inc. | Crystalline forms of (S) 2 ethylbutyl 2 (((S) (((2R,3S,4R,5R) 5 (4 aminopyrrolo[2,1-f] [1,2,4]triazin-7-yl)-5-cyano-3,4-dihydroxytetrahydrofuran-2 yl)methoxy)(phenoxy) phosphoryl)amino)propanoate |
US10675296B2 (en) | 2017-07-11 | 2020-06-09 | Gilead Sciences, Inc. | Compositions comprising an RNA polymerase inhibitor and cyclodextrin for treating viral infections |
US20210008195A1 (en) | 2017-12-20 | 2021-01-14 | Zoetis Services Llc | Vaccines against hendra and nipah virus infection |
CN110951922A (zh) * | 2019-12-25 | 2020-04-03 | 中国动物卫生与流行病学中心 | 一种检测亨德拉病毒的raa引物探针及检测方法 |
TWI789695B (zh) | 2020-01-27 | 2023-01-11 | 美商基利科學股份有限公司 | 治療sars cov-2感染之方法 |
TWI785528B (zh) | 2020-03-12 | 2022-12-01 | 美商基利科學股份有限公司 | 1’-氰基核苷之製備方法 |
EP4132651A1 (en) | 2020-04-06 | 2023-02-15 | Gilead Sciences, Inc. | Inhalation formulations of 1'-cyano substituted carbanucleoside analogs |
EP4157272A1 (en) | 2020-05-29 | 2023-04-05 | Gilead Sciences, Inc. | Remdesivir treatment methods |
BR112022026321A2 (pt) | 2020-06-24 | 2023-01-17 | Gilead Sciences Inc | Análogos de 1'-ciano nucleosídeo e usos dos mesmos |
US11926645B2 (en) | 2020-08-27 | 2024-03-12 | Gilead Sciences, Inc. | Compounds and methods for treatment of viral infections |
US20220193225A1 (en) * | 2020-08-31 | 2022-06-23 | Bruce Lyday | Compositions and methods for sars-2 vaccine with virus replicative particles and recombinant glycoproteins |
WO2022270656A1 (ko) * | 2021-06-24 | 2022-12-29 | 진철 | 금 나노입자를 유효성분으로 포함하는 니파 바이러스의 예방 또는 치료용 조성물 |
TW202400185A (zh) | 2022-03-02 | 2024-01-01 | 美商基利科學股份有限公司 | 用於治療病毒感染的化合物及方法 |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SE8205892D0 (sv) | 1982-10-18 | 1982-10-18 | Bror Morein | Immunogent membranproteinkomplex, sett for framstellning och anvendning derav som immunstimulerande medel och sasom vaccin |
SE8405493D0 (sv) | 1984-11-01 | 1984-11-01 | Bror Morein | Immunogent komplex samt sett for framstellning derav och anvendning derav som immunstimulerande medel |
AU614755B2 (en) | 1987-06-05 | 1991-09-12 | United States of America, as represented by the Secretary, U.S. Department of Commerce, The | Autocrine motility factors in cancer diagnosis and management |
NZ230747A (en) | 1988-09-30 | 1992-05-26 | Bror Morein | Immunomodulating matrix comprising a complex of at least one lipid and at least one saponin; certain glycosylated triterpenoid saponins derived from quillaja saponaria molina |
SE9600647D0 (sv) | 1996-02-21 | 1996-02-21 | Bror Morein | Ny användning |
AUPO517897A0 (en) * | 1997-02-19 | 1997-04-11 | Csl Limited | Chelating immunostimulating complexes |
GB9817052D0 (en) | 1998-08-05 | 1998-09-30 | Smithkline Beecham Biolog | Vaccine |
AUPP807399A0 (en) | 1999-01-08 | 1999-02-04 | Csl Limited | Improved immunogenic lhrh composition and methods relating thereto |
US20050287170A1 (en) * | 2002-12-11 | 2005-12-29 | Hawaii Biotech, Inc. | Subunit vaccine against West Nile viral infection |
AU2004274717A1 (en) * | 2003-09-22 | 2005-03-31 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | A method for detecting Nipah virus and method for providing immunoprotection against henipaviruses |
CN1882704A (zh) * | 2003-09-22 | 2006-12-20 | 巴斯德研究院 | 尼帕病毒检测方法和提供抗汉尼巴病毒的免疫保护的方法 |
EP1789593B1 (en) * | 2004-07-09 | 2017-03-15 | The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. | Soluble forms of hendra virus g glycoprotein |
WO2006137931A2 (en) | 2005-03-14 | 2006-12-28 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Serivces | Human monoclonal antibodies against hendra and nipah viruses |
WO2006115843A2 (en) * | 2005-04-25 | 2006-11-02 | Merial Limited | Nipah virus vaccines |
WO2009117035A1 (en) | 2007-12-19 | 2009-09-24 | The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. | Soluble forms of hendra and nipah virus f glycoprotein and uses thereof |
-
2012
- 2012-05-14 UA UAA201314534A patent/UA114086C2/uk unknown
- 2012-05-14 ES ES17180615T patent/ES2963147T3/es active Active
- 2012-05-14 JP JP2014510547A patent/JP2014516955A/ja active Pending
- 2012-05-14 AU AU2012256000A patent/AU2012256000B2/en active Active
- 2012-05-14 BR BR112013029309A patent/BR112013029309A8/pt not_active Application Discontinuation
- 2012-05-14 EP EP12785009.7A patent/EP2707025B8/en active Active
- 2012-05-14 KR KR1020137033274A patent/KR20140053906A/ko active Application Filing
- 2012-05-14 ES ES12785009.7T patent/ES2639122T3/es active Active
- 2012-05-14 EP EP17180615.1A patent/EP3251692B1/en active Active
- 2012-05-14 CN CN201280033736.8A patent/CN104244974A/zh active Pending
- 2012-05-14 MX MX2013013277A patent/MX352604B/es active IP Right Grant
- 2012-05-14 CA CA2836098A patent/CA2836098C/en active Active
- 2012-05-14 CN CN201910445312.6A patent/CN110680913A/zh active Pending
- 2012-05-14 RU RU2013155470A patent/RU2681529C2/ru not_active IP Right Cessation
- 2012-05-14 WO PCT/US2012/037839 patent/WO2012158643A1/en active Application Filing
- 2012-05-14 KR KR1020207010055A patent/KR20200040899A/ko not_active IP Right Cessation
- 2012-05-14 PT PT127850097T patent/PT2707025T/pt unknown
- 2012-05-14 US US14/117,516 patent/US20150050305A1/en not_active Abandoned
-
2013
- 2013-11-13 CO CO13267208A patent/CO6940373A2/es unknown
- 2013-11-13 CL CL2013003248A patent/CL2013003248A1/es unknown
- 2013-11-20 ZA ZA2013/08701A patent/ZA201308701B/en unknown
-
2014
- 2014-09-18 HK HK18107349.3A patent/HK1247833A1/zh unknown
-
2017
- 2017-04-06 JP JP2017076265A patent/JP6898024B2/ja active Active
- 2017-08-10 AU AU2017213501A patent/AU2017213501A1/en not_active Abandoned
- 2017-09-22 JP JP2017182552A patent/JP2018030862A/ja active Pending
-
2019
- 2019-04-11 JP JP2019075881A patent/JP2019142909A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CL2013003248A1 (es) | Composición inmunogenica que comprende una glucoproteina g de los virus hendra y nipah y un complejo inmunoestimulante; método para producir una respuesta de anticuerpo neutralizante contra un virus hendra y/o nipah en un sujeto. | |
Cruz-Oliveira et al. | Receptors and routes of dengue virus entry into the host cells | |
US9701723B2 (en) | Vaccines for use in the prophylaxis and treatment of influenza virus disease | |
US9708373B2 (en) | Influenza virus vaccine and uses thereof | |
US10736956B2 (en) | Influenza virus vaccination regimens | |
US11684669B2 (en) | CpG-adjuvanted SARS-CoV-2 virus vaccine | |
BRPI0707300B8 (pt) | vacina contra vírion influenza dividido ou antígeno de superfície purificado e método para a preparação de uma composição imunogênica | |
SI3079715T1 (en) | A mixture of peptides | |
AR095432A1 (es) | Proteínas de unión a antígeno | |
BRPI0911699B8 (pt) | vetor, célula, composição farmacêutica, uso de um anticorpo, ou fragmento de ligação a antígeno deste | |
PE20190420A1 (es) | Proteinas f de prefusion del virus respiratorio sincicial (vrs) solubles y estabilizadas | |
ES2721882T3 (es) | Regiones constantes de anticuerpo modificadas por ingeniería genética para conjugación específica de sitio y procedimientos y usos de las mismas | |
AR073452A1 (es) | Proteinas de fusion que comprende dos o mas antigenos de leishmania y su uso en el diagnostico y tratamiento de leishmaniasis | |
BR112014004860A2 (pt) | composições de anticorpo contra vírus da influenza | |
BRPI1011540A2 (pt) | anticorpos anticxcr4 para o tratamento de of hiv | |
ES2421543T3 (es) | Método para la preparación de virus y proteínas del PRRS, y kits de pruebas de diagnóstico para su detección | |
CL2008002092A1 (es) | Conjugado que contiene dos o mas peptidos antifusogenicos y un anticuerpo anti-cd-4; metodo de produccion; composicion farmaceutica que lo comprende; polipeptidos antifusogenicos y uso del conjugado para tratar infecciones viricas. | |
JP2022527235A (ja) | インフルエンザウイルスにおける付加的遺伝子に遺伝的安定性を付与する突然変異 | |
HRP20171697T1 (hr) | Varijanta hiv gp-120 | |
RU2015130287A (ru) | Адаптация вируса гриппа н5 к человеку | |
Xu et al. | Detection of viral components in exosomes derived from NDV-infected DF-1 cells and their promoting ability in virus replication | |
CL2011003002A1 (es) | Anticuerpo monoclonal o un fragmento del mismo que se une a la proteina m2-1 del virus respiratorio sincicial (vrs) humano; secuencias nucleotidicas; composicion farmaceutica; metodo de diagnostico de infeccion producida por vrs; kit; y uso de dicho anticuerpo para preparar un medicamento. | |
EP3497119A1 (en) | Modulation of ifi16 and sting activity | |
AR087654A1 (es) | METODO DIAGNOSTICO DE ANIMALES VACUNADOS CON PESTIVIRUS QUIMERICO EN EL CUAL LA PROTEINA Eʳⁿˢ DEL VIRUS DE LA DIARREA VIRAL BOVINA (BVDV) ES REMPLAZADA POR PROTEINA Eʳⁿˢ DE PESTIVIRUS DE ANTILOPE AMERICANO | |
Gunay et al. | Peptide aggregation induced immunogenic rupture (PAIIR) |